Gilenya and Cardiac flutter - a phase IV clinical study of FDA data

Summary:

Cardiac flutter is found among people who take Gilenya, especially for people who are female, 40-49 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Gilenya and have Cardiac flutter. It is created by eHealthMe based on reports of 106,924 people who have side effects when taking Gilenya from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 30, 2023

106,924 people reported to have side effects when taking Gilenya.
Among them, 104 people (0.1%) have Cardiac flutter.

What is Gilenya?

Gilenya has active ingredients of fingolimod. It is often used in multiple sclerosis. eHealthMe is studying from 107,199 Gilenya users for its effectiveness, alternative drugs and more.

What is Cardiac flutter?

Cardiac flutter (abnormal heart rhythm) is found to be associated with 1,207 drugs and 645 conditions by eHealthMe.

Number of Gilenya and Cardiac flutter reports submitted per year:

* Approximation only. Some reports may have incomplete information.

Do you take Gilenya and have Cardiac flutter?

Check whether Cardiac flutter is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

Related studies

How severe was Cardiac flutter and when was it recovered:

Cardiac flutter in Gilenya

Expand to all the drugs that have ingredients of fingolimod:

Cardiac flutter and drugs with ingredients of fingolimod

Alternative drugs to, pros and cons of Gilenya:

Gilenya (107,199 reports)

Common Gilenya side effects:

Fatigue (feeling of tiredness): 15,662 reports
Headache (pain in head): 10,434 reports
Dizziness: 8,494 reports
Weakness: 7,025 reports

Browse all side effects of Gilenya:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Cardiac flutter treatments and more:

Cardiac flutter (6,651 reports)

COVID vaccines that are related to Cardiac flutter:

Common drugs associated with Cardiac flutter:

All the drugs that are associated with Cardiac flutter:

Cardiac flutter (1,207 drugs)

Common conditions associated with Cardiac flutter:

Multiple sclerosis: 381 reports
High blood pressure: 325 reports
Primary pulmonary hypertension: 273 reports
High blood cholesterol: 252 reports
Rheumatoid arthritis: 231 reports
Atrial fibrillation/flutter: 207 reports
Osteoporosis: 143 reports
Pain: 138 reports

All the conditions that are associated with Cardiac flutter:

Cardiac flutter (645 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fingolimod (the active ingredients of Gilenya) and Gilenya (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.